Haemonetics (HAE)
(Delayed Data from NYSE)
$74.83 USD
-0.25 (-0.33%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $74.78 -0.05 (-0.07%) 6:24 PM ET
2-Buy of 5 2
B Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.83 USD
-0.25 (-0.33%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $74.78 -0.05 (-0.07%) 6:24 PM ET
2-Buy of 5 2
B Value F Growth F Momentum F VGM
Zacks News
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.
Walgreens, UnitedHealthcare Team Up to Boost Medicare Services
by Zacks Equity Research
Walgreens (WBA) partners with UnitedHealthcare to further strengthen the Medicare coverage for its customers.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
NuVasive Gets FDA Nod for CoRoent Small Interlock System
by Zacks Equity Research
NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.
Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds
by Zacks Equity Research
Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.
Henry Schein to Showcase New Dental Offerings at GNYDM
by Zacks Equity Research
Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.
Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan
by Zacks Equity Research
The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.
Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Dexcom (DXCM) gains from several positive developments.
Myriad Genetics' Test Added in Disease Activity Measure List
by Zacks Equity Research
Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.
Hologic (HOLX) Set to Divest Medical Aesthetics Business
by Zacks Equity Research
Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.
Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge
by Zacks Equity Research
The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.
QIAGEN Expands Existing Deal With LabCorp for Better Treatment
by Zacks Equity Research
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
Option Care is the Preferred Provider of Haemophilia Treatment
by Zacks Equity Research
Option Care Health (BIOS) can currently access all hemophilia factor treatments.
Here's Why You Should Hold GNC Holdings (GNC) Stock for Now
by Zacks Equity Research
Investors can still retain GNC Holdings (GNC) in their portfolio, thanks to solid prospects.
Safety Notice Issued by Boston Scientific (BSX) for AngioJet
by Zacks Equity Research
Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.
Smith & Nephew's Study Outcomes for REGENETEN Encouraging
by Zacks Equity Research
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.
Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.
Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath
by Zacks Equity Research
Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.
InMode (INMD) Looks Good: Stock Adds 5.6% in Session
by Zacks Equity Research
InMode (INMD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
by Zacks Equity Research
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
Amedisys Partners With nVoq to Improve Clinician Experience
by Zacks Equity Research
Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.
New Strong Buy Stocks for November 18th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Haemonetics (HAE) Grows on New Products, Robust Plasma Sales
by Zacks Equity Research
Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.
Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has been gaining from several positive developments recently.